From: The effect of varying analytical methods on estimates of anti-malarial clinical efficacy
Outcome Category | Outcome Code | Outcome Definition | Africa | Thailand | Total |
---|---|---|---|---|---|
Follow-up completed | 0 | ACPR | 4385 | 4604 | 8989 |
 | 1 | ETF with death | 0 | 1 | 1 |
 | 2 | ETF with severe malaria | 5 | 0 | 5 |
 | 3 | ETF with danger signs | 39 | 0 | 39 |
 | 4 | ETF with parasitological criteria | 58 | 1 | 59 |
 | 5 | ETF with clinical criteria | 9 | 0 | 9 |
 | 6 | ETF not otherwise specified | 0 | 11 | 11 |
 | 7 | LCF with death | 0 | 0 | 0 |
 | 8 | LCF with severe malaria | 0 | 0 | 0 |
 | 9 | LCF with danger signs | 4 | 0 | 4 |
 | 10 | LCF with fever | 1033 | 654 | 1687 |
 | 11 | LPF | 1726 | 665 | 2391 |
 | 12 | LPF/LCF indistinguishable | 0 | 737 | 737 |
Follow-up interrupted | 13 | Adverse event requiring change in anti-malarial therapy | 0 | 2 | 2 |
 | 14 | Treatment protocol violation | 4 | 138 | 142 |
 | 15 | Death not due to malaria | 0 | 3 | 3 |
 | 16 | Lost to follow-up | 175 | 955 | 1130 |
 | 17 | Use of other anti-malarials outside of study protocol | 48 | 6 | 54 |
 | 18 | Withdrawal of consent prohibiting further follow-up | 126 | 1 | 127 |
 | 19 | Investigator initiated withdrawal from further follow-up | 7 | 0 | 7 |
 | 20 | Patient who does not complete follow-up for any other reason | 0 | 12 | 12 |